In fact, ABC-DLBCL cells were more sensitive than GCB-DLBCLs (that are not reliant on NF-κB) [27] suggesting that this drug may be more efficacious for cancers such as PEL and KS, where NF-κB activation is a requirement for malignancy. This evidence concerns the gene NFKB1 and Kaposi's sarcoma.